AstraZeneca sweeps away the MedImmune name as CEO Soriot restructures R&D
MedImmune is history.
AstraZeneca execs acknowledged today that the company is sweeping the MedImmune brand name away as CEO Pascal Soriot streamlines the R&D organization, carving the group into 2 parts.
Basic subscription required
Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.